[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Investigation Report on Chinese Clopidogrel Market 2021-2025

April 2021 | 50 pages | ID: I91C9C4A5129EN
China Research and Intelligence Co., Ltd.

US$ 2,600.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Clopidogrel is a medication that inhibits platelet aggregation and is mainly used to prevent atherosclerotic thrombosis. The original drug, Plavix, is developed by Sanofi. It enters the Chinese market in 2001. In addition to Sanofi, the other main manufacturers of Clopidogrel in the Chinese market are Salubris Pharmaceuticals, Lepu Pharmaceutical, and CSPC Ouyi Pharmaceutical.

According to CRI’s market research, the sales revenue of Clopidogrel in China has been decreasing since 2018, the sales value of Clopidogrel in China was approximately CNY680 million, and the CAGR is -21.9% in 2016 to 2020. The decrease in sales is mainly due to the impact of centralized procurement and the appearance of alternative drugs. Nevertheless, as the antithrombotic market keeps expanding, Clopidogrel will still have considerable annual sales in the short term. In addition, the price of Clopidogrel has been greatly reduced because of centralized procurement. Thus, some people may be more willing to choose Clopidogrel instead of other biosimilar drugs. CRI concludes that as the epidemic situation improves, Clopidogrel sales in China is expected to have a restorative growth, and it will also become more stable from 2022 to 2025.

Topics Covered:
  • The impact of COVID-19 on China's Clopidogrel market
  • Sales value and volume of China's Clopidogrel 2016-2020
  • Competitive landscape of China's Clopidogrel market
  • Prices of Clopidogrel in China
  • Prices of Clopidogrel in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Clopidogrel market
  • Prospect of China's Clopidogrel market from 2021 to 2025
1 RELEVANT CONCEPTS OF CLOPIDOGREL

1.1 Indications for Clopidogrel
1.2 Development of Clopidogrel in China
1.3 Governmental Approval of Clopidogrel in China
1.4 The Impact of COVID-19 on Clopidogrel sales in China

2 SALES OF CLOPIDOGREL IN CHINA, 2016-2020

2.1 Sales Value of Clopidogrel
  2.1.1 Overall Sales Value
  2.1.2 Sales Value by Region
2.2 Sales Volume of Clopidogrel
  2.2.1 Overall Sales Volume
  2.2.2 Sales Volume by Region
2.3 Sales of Clopidogrel by Dosage Form in China, 2016-2020
  2.3.1 Tablet
  2.3.2 Analysis of Other Dosage Forms

3 ANALYSIS OF MAJOR CLOPIDOGREL MANUFACTURERS IN CHINA, 2016-2020

3.1 Analysis of Market Share of Major Clopidogrel Manufacturers
  3.1.1 Investigation on Market Share by Sales Value
  3.1.2 Investigation on Market Share by Sales volume
3.2 Shenzhen Salubris Pharmaceuticals Co., Ltd.
  3.2.1 Enterprise Profile
  3.2.2 Sales of Taijia (Salubris’ Clopidogrel) in China
3.3 Sanofi (Hangzhou) Pharmaceutical Co., Ltd.
  3.3.1 Enterprise Profile
  3.3.2 Sales of Plavix (Sanofi (Hangzhou)’s Clopidogrel) in China
3.4 Sanofi-aventis groupe
  3.4.1 Enterprise Profile
  3.4.2 Sales of Plavix (Sanofi-aventis groupe’s Clopidogrel) in China
3.5 Lepu Pharmaceutical Co., Ltd.
  3.5.1 Enterprise Profile
  3.5.2 Sales of Clopidogrel Hydrogen Sulfate Tablets (Lepu’s Clopidogrel) in China
3.6 CSPC Ouyi Pharmaceutical Group Co., Ltd.
  3.6.1 Enterprise Profile
  3.6.2 Sales of Clopidogrel Bisulfate Tablets (CSPC OUYI’s Clopidogrel) in China

4 PRICES OF CLOPIDOGREL FOR DIFFERENT MANUFACTURERS IN CHINA, 2020-2021

4.1 Shenzhen Salubris Pharmaceuticals Co., Ltd. (Taijia)
4.2 Sanofi (Hangzhou) Pharmaceutical Co., Ltd. (Plavix)
4.3 Sanofi-aventis groupe (Plavix)
4.4 Lepu Pharmaceutical Co., Ltd. (Shuaitai)
4.5 CSPC Ouyi Pharmaceutical Co., Ltd. (EnCun)

5 PROSPECT OF CHINESE CLOPIDOGREL DRUG MARKET, 2021-2025

5.1 Influential Factors of Chinese Clopidogrel Market Development
  5.1.1 The Impact of COVID-19 on Chinese Clopidogrel Market
  5.1.2 Market Drivers and Opportunities
  5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

LIST OF CHARTS

Chart Patent Information About Clopidogrel Tablet Registration in China
Chart Sales Value of Clopidogrel Tablet over the world
Chart Sales Value of Clopidogrel Tablet in China,2016-2020
Chart Sales Value of Clopidogrel Tablet in China by Regions, 2016-2020
Chart Sales Volume of Clopidogrel Tablet in China, 2016-2020
Chart Sales Volume of Clopidogrel Tablet in China by Regions, 2016-2020
Chart Market Share by Sales Value of Top Clopidogrel Manufacturers in China, 2016-2020
Chart Sales Value and Volume of Taijia in China, 2016-2020
Chart Sales Value and Volume of Plavix (Sanofi (Hangzhou)’s Clopidogrel) in China, 2016-2020
Chart Sales Value and Volume of Plavix (Sanofi-aventis groupe’s Clopidogrel) in China, 2016-2020
Chart Sales Value and Volume of Shuaitai in China, 2016-2020
Chart Sales Value and Volume of EnCun in China, 2016-2020
Chart Referential Prices of Taijia in China, 2020-2021
Chart Referential Prices of Plavix (Sanofi (Hangzhou)’s Clopidogrel) in China, 2020-2021
Chart Referential Prices of Plavix (Sanofi-aventis groupe’s Clopidogrel) in China, 2020-2021
Chart Referential Prices of Shuaitai in China, 2020-2021
Chart Referential Prices of EnCun in China, 2020-2021
Chart Forecast on Sales Value of Clopidogrel in China, 2021-2025
Chart Forecast on Sales Volume of Clopidogrel in China, 2021-2025


More Publications